Literature DB >> 17235319

Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.

Scott E Hensley1, Ann S Cun, Wynetta Giles-Davis, Yan Li, Zhiquan Xiang, Marcio O Lasaro, Bryan R G Williams, Robert H Silverman, Hildegund C J Ertl.   

Abstract

Recent studies have indicated that type I interferon (IFN) enhances antibody responses and promotes isotype switching. In this study, we analyzed the role of type I IFN signaling during the generation of transgene product-specific antibody responses elicited by recombinant adenovirus (Ad) vectors. A vector derived from a human Ad serotype (AdHu5) induced low levels of type I IFN following infection of dendritic cells (DCs) and stimulated normal transgene product-specific antibody responses in mice that have a defective type I IFN receptor (IFNAR(-/-)). A vector derived from a chimpanzee Ad serotype (AdC68) induced very high levels of type I IFN following infection of DCs, and surprisingly, primed stronger transgene product-specific antibody responses in IFNAR(-/-) mice compared to wild-type mice. The increased antibody response in IFNAR(-/-) mice vaccinated with the AdC68 vector was mainly due to the generation of IgG1 antibodies that were not elicited in wild-type mice. The induction of IgG1 antibodies correlated with an increase in transgene product expression in IFNAR(-/-) mice and was not associated with an increase in T helper 2 responses. We conclude that type I IFN, when induced at high levels, can downregulate transgene product expression of Ad vectors and inhibit the formation of optimal antibody responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235319     DOI: 10.1038/sj.mt.6300024

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  43 in total

1.  TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.

Authors:  D M Appledorn; S Patial; S Godbehere; N Parameswaran; A Amalfitano
Journal:  J Innate Immun       Date:  2009-03-04       Impact factor: 7.349

2.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

Review 3.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

4.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.

Authors:  Susan L Pichla-Gollon; Shih-Wen Lin; Scott E Hensley; Marcio O Lasaro; Larissa Herkenhoff-Haut; Mark Drinker; Nia Tatsis; Guang-Ping Gao; James M Wilson; Hildegund C J Ertl; Jeffrey M Bergelson
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Authors:  Joseph T Bruder; Ping Chen; Elena Semenova; Charlie A Thomas; Svetlana Konovalova; Greg Ekberg; Damodar Ettyreddy; Duncan McVey; Jason G Gall; C Richter King; Douglas E Brough
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

7.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 8.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

9.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

10.  Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.

Authors:  Zachary C Hartman; Daniel M Appledorn; Delila Serra; Oliver Glass; Todd B Mendelson; Timothy M Clay; Andrea Amalfitano
Journal:  Virology       Date:  2008-02-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.